Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Cancelled (Unreturned Annual)
Current status date:
2023-01-09
Original market date: See footnote 1
Product name:
HALOPERIDOL INJECTION
DIN:
02493993
Product Monograph/Veterinary Labelling:
Date:
2019-11-07
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
NEO HEALTH CANADA INC.
1900
300 Leo Pariseau
Montreal
Quebec
Canada
H2X 4B5
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
28:16.08.08
Anatomical Therapeutic Chemical (ATC): See footnote 4
N05AD01 HALOPERIDOL
Active ingredient group (AIG) number:See footnote5
0101774001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| HALOPERIDOL | 5 MG / ML |